PMID- 28710695
OWN - NLM
STAT- MEDLINE
DCOM- 20180502
LR  - 20181202
IS  - 1435-165X (Electronic)
IS  - 1018-8827 (Linking)
VI  - 27
IP  - 1
DP  - 2018 Jan
TI  - Serum brain-derived neurotrophic factor levels in treatment-naive boys with 
      attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, 
      observational pretest-posttest study.
PG  - 127-135
LID - 10.1007/s00787-017-1022-y [doi]
AB  - Brain-derived neurotrophic factor (BDNF) is an important neurotrophin in the 
      brain that modulates dopaminergic neurons. In this study, we aimed to investigate 
      the changes in serum BDNF levels of children with attention-deficit/hyperactivity 
      disorder (ADHD) in response to OROS methylphenidate treatment. We also aimed to 
      determine whether there were any pre-post-differences between ADHD subtypes and 
      comorbid psychiatric disorders in serum BDNF levels. Fifty male children with 
      ADHD and 50 male healthy controls within the age range of 6-12 years were 
      recruited to the study. The psychiatric diagnoses were determined by applying a 
      structured interview with Kiddie schedule for affective disorders and 
      schizophrenia for school-age children-present and lifetime version. The symptom 
      severity of ADHD was measured using the Clinical Global Impression ADHD Severity 
      Scale (CGI-S). Physicians completed Du Paul ADHD questionnaires. The levels of 
      serum BDNF were assessed before and after 8 weeks of treatment with effective 
      dosages of OROS methylphenidate. In the present study, the mean serum BDNF levels 
      of boys with ADHD and of the healthy controls were 2626.33 +/- 1528.05 and 
      2989.11 +/- 1420.08 pg/mL, respectively. Although there were no statistically 
      significant difference between the ADHD group and healthy controls at baseline 
      (p = 0.22), the increase of serum BDNF was statistically significant from 
      baseline to endpoint in the ADHD group (p = 0.04). The mean serum BDNF levels at 
      baseline and endpoint of the ADHD group were 2626.33 +/- 1528.05 and 
      3255.80 +/- 1908.79 pg/mL, respectively. The serum BDNF levels of ADHD-inattentive 
      subtype were significantly lower at baseline (p = 0.02), whereas BDNF levels 
      post-treatment showed no significant difference. The increase of serum BDNF 
      levels with methylphenidate treatment after 8 weeks was significantly higher in 
      the inattentive group (p = 0.005). The increase of serum BDNF levels with 
      methylphenidate treatment after 8 weeks in boys with ADHD may support the 
      potential role of BDNF in the pathophysiology of ADHD. The role of BDNF in ADHD 
      subtypes in particular should be evaluated with further, larger studies.
FAU - Akay, Aynur Pekcanlar
AU  - Akay AP
AD  - Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical 
      Faculty, Izmir, Turkey.
FAU - Resmi, Halil
AU  - Resmi H
AD  - Department of Biochemistry, Dokuz Eylul University Medical Faculty, Izmir, 
      Turkey.
FAU - Guney, Sevay Alsen
AU  - Guney SA
AD  - Department of Child and Adolescent Psychiatry, Dokuz Eylul University Medical 
      Faculty, Izmir, Turkey.
FAU - Erkuran, Handan Ozek
AU  - Erkuran HO
AD  - Izmir Dr. BehcetUz Training and Research Hospital for Pediatric Disorders and 
      Surgery, Izmir, Turkey.
FAU - Ozyurt, Gonca
AU  - Ozyurt G
AD  - Department of Child and Adolescent Psychiatry, Katip Celebi University Medical 
      Faculty, Izmir, Turkey. goncaenginozyurt@gmail.com.
FAU - Sargin, Enis
AU  - Sargin E
AD  - Izmir Tepecik Training and Research Hospital, Izmir, Turkey.
FAU - Topuzoglu, Ahmet
AU  - Topuzoglu A
AD  - Department of Public Health, Kurtalan State Hospital, Siirt, Turkey.
FAU - Tufan, Ali Evren
AU  - Tufan AE
AD  - Department of Child and Adolescent Psychiatry, Abant Izzet Baysal University 
      Medical Faculty, Bolu, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20170714
PL  - Germany
TA  - Eur Child Adolesc Psychiatry
JT  - European child & adolescent psychiatry
JID - 9212296
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Central Nervous System Stimulants)
RN  - 207ZZ9QZ49 (Methylphenidate)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Central Nervous System Stimulants/*therapeutic use
MH  - Child
MH  - Humans
MH  - Male
MH  - Methylphenidate/*therapeutic use
MH  - Time Factors
OTO - NOTNLM
OT  - Attention-deficit/hyperactivity disorder
OT  - Brain-derived neurotrophic factor
OT  - Children
OT  - Methylphenidate
EDAT- 2017/07/16 06:00
MHDA- 2018/05/03 06:00
CRDT- 2017/07/16 06:00
PHST- 2017/03/09 00:00 [received]
PHST- 2017/06/29 00:00 [accepted]
PHST- 2017/07/16 06:00 [pubmed]
PHST- 2018/05/03 06:00 [medline]
PHST- 2017/07/16 06:00 [entrez]
AID - 10.1007/s00787-017-1022-y [pii]
AID - 10.1007/s00787-017-1022-y [doi]
PST - ppublish
SO  - Eur Child Adolesc Psychiatry. 2018 Jan;27(1):127-135. doi: 
      10.1007/s00787-017-1022-y. Epub 2017 Jul 14.